Therefore, this article reviews the mechanisms of CDK4/6 inhibitors in NSCLC, monotherapy using CDK4/6 inhibitors, and the effects of combining them with other drugs in the context of NSCLC treatment. Here, CDK4 is linked to non-small cell lung carcinoma.